0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Treatment of Hypercalcemia in Parathyroid Cancer with WR-2721,5-2(3aminopropylamino) Ethyl-Phosphorothioic Acid

DONNA J. GLOVER, M.D.; LESLIE SHAW, Ph.D.; JOHN H. GLICK, M.D.; EDUARDO SLATOPOLSKY, M.D.; CLARE WEILER, R.N.; MAURICE ATTIE, M.D.; and STANLEY GOLDFARB, M.D.
[+] Article and Author Information

Grant support: in part by research grants ROl AM-31826-02 and AM-09976, and training grant AM-07006, from the National Institutes of Health; and grants CA-301000 and CA-16520 from the National Cancer Institutes. Dr. Glover is a recipient of an American Cancer Society Junior Faculty Clinical Fellowship. Dr. Glick is a recipient of a Faculty Research Award from the American Cancer Society.

▸ Requests for reprints should be addressed to Donna J. Glover, M.D.; Hematology-Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street; Philadelphia, PA 19104.


Philadelphia, Pennsylvania; and St. Louis, Missouri


© 1985 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1985;103(1):55-57. doi:10.7326/0003-4819-103-1-55
Text Size: A A A

The chemoprotective and hypocalcemic agent WR-2721, S-2-(3-aminopropylamino) ethyl-phosphorothioic acid, inhibits parathyroid hormone secretion in vivo and in vitro. We report the first clinical use of WR-2721 in refractory hypercalcemia secondary to parathyroid cancer. After several days of saline diuresis the patient received WR-2721, 740 mg/m2 over 15 minutes, resulting in a fall in serum calcium from 11.76 to 9.06 mg/dL within 24 hours. Serum parathyroid hormone levels decreased from 675 to 140 µLeq/mL 2 hours after the infusion was complete. When hypercalcemia recurred the patient was retreated with differing doses and infusion rates to determine the optimal method of drug administration to provide a satisfactory hypocalcemic response without adverse effects. In this patient, WR-2721 in intravenous boluses of 150 mg/m2 was effective without adverse effects. Using high-pressure liquid chromatography with electrochemical detection, plasma pharmacokinetic studies showed that WR-2721 's distribution half-life is 0.55 minutes.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
[Primary hyperparathyroidism]. Praxis (Bern 1994) 2013;102(23):1399-404; quiz 1405-6.
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)